Analgesic effects of the cathepsin K inhibitor L-006235 in the monosodium iodoacetate model of osteoarthritis pain by Nwosu, Lilian N. et al.
D
ow
nloaded
from
https://journals.lw
w
.com
/painrpts
by
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
3yR
lX
g5V
ZA
8vvJz0Tn6A
01LD
B
k4ZrC
P
i670JA
ZIvm
6oI=
on
10/17/2018
Downloadedfromhttps://journals.lww.com/painrptsbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3yRlXg5VZA8vvJz0Tn6A01LDBk4ZrCPi670JAZIvm6oI=on10/17/2018
Basic Science
Research Paper
Analgesic effects of the cathepsin K inhibitor
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Abstract
Introduction: The mounting evidence that osteoclasts play an important role in osteoarthritis (OA) pain lead us to investigate the
effects of L-006235, a potent and selective inhibitor of cathepsin K, on pain behaviour and joint pathology in a model of OA pain.
Methods: Effects of preventative (30 and 100 mg/kg) and therapeutic (100 mg/kg) oral dosing with L-006235 on weight-bearing
asymmetry, hind pawwithdrawal thresholds, cartilage and bone pathology, synovial inflammation, and drug exposure were studied
in the monosodium iodoacetate rat model of OA pain.
Results: Preventative L-006235 inhibited weight-bearing asymmetry from day 14, with this measure nearly abolished by the higher
dose. In the same treatment setting, L-006235 prevented lowering of hind paw withdrawal thresholds from day 7. Exposure to
L-006235 in plasma was higher for the 100mg/kg dose, compared with 30 mg/kg. Therapeutic dosing with L-006235 from day 14
significantly inhibited weight-bearing asymmetry, compared with monosodium iodoacetate vehicle rats. Regression analysis
revealed a significant interaction coefficient of the effects of L-006235 on weight-bearing asymmetry and synovitis score, but not for
cartilage damage nor osteophyte scores.
Conclusion:Our novel finding that cathepsin K inhibition is analgesic in a clinically relevant model of OA pain provides new evidence
for the therapeutic potential of this target.
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1. Introduction
Osteoarthritis (OA) is the fastest growing chronic pain disease31,46
and is the most common form of arthritis, causing disability and
reducing quality of life.11 Although OA was considered to be
primarily a disease of the cartilage, clinical and preclinical evidence
supports bidirectional interactions between cartilage and sub-
chondral bone turnover in OA. The contribution of subchondral
bone mechanisms to the pathogenesis and progression of OA is
increasingly recognised.20
Animalmodelsmimic keyaspects ofOA joint pathology andpain
behaviour (see references in Ref. 44). The monosodium iodoace-
tate (MIA) model is associated with pain behaviour on weight-
bearing, lowering of distal pain pressure threshold, synovial
inflammation, cartilage damage, and subchondral bone remodel-
ling including increased osteoclast number and numbers of
osteochondral channels and osteophyte formation.47 Numbers
of subchondral bone osteoclasts are significantly and positively
associated with pain behaviour in the MIA model.37 Cathepsin K is
a cysteine protease predominantly expressed by osteoclasts and
involved in bone resorption,3 under normal physiological con-
ditions; this enzyme degrades bone matrix proteins, such as type I
collagen. In OA, cathepsin K also degrades the main components
of cartilage matrix, type II collagen and aggrecan.7 Expression of
cathepsin K and the osteoclast marker TRAP is increased in
humanOAbone.27 Cathepsin KmRNA and protein expression are
increased in synovial fibroblasts and CD681 macrophages in
human OA samples,8,25 and expression in chondrocytes is
increased in relation to OA severity.23
Overexpression of cathepsin K leads to spontaneous synovitis
and cartilagedegeneration,30,33 and this enzymehas been strongly
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implicated in the degradation of articular cartilage in a naturally
occurring equine model of OA.43 Inhibitors of cathepsin K
attenuated lesion severity and biomarkers of collagen degradation
in a canine model of OA.6,26 Similarly, significant protective effects
of cathepsin K inhibition on subchondral bone integrity were
reported in a rabbitmodel of OA.14,26 Although effects of cathepsin
K inhibition on OA pain behaviour have yet to be reported, such
a treatment reduced the mechanosensitivity of knee afferent nerve
activity in a guineapigmodel of spontaneousOA,29 suggesting that
cathepsin K inhibition might reduce aberrant OA pain.
The aim of this study was to evaluate the effects of inhibition of
cathepsin K on pain behaviour and joint pathology in a rat model
of OA. L-006235 is a potent and selective cathepsin K inhibitor
with oral bioavailability and more than 5000-fold selective for
cathepsin K vs cathepsins B, L, and S.32 L-006235 is potent
against rat cathepsin K with an IC50 of 7 nM. Previously,
prophylactic L-006235 reduced histological markers of disease
severity in a murine model of inflammatory arthritis.41 In this
article, we have used the MIA model of OA pain to investigate the
effects of L-006235 on the development of pain behaviour, joint
pathology, and a spinal marker of central sensitization in the rat.
Separately, the ability of L-006235 to reverse established pain
behaviour in this model of OA joint pain was investigated.
2. Methods
2.1. Animals
All animal experimental procedures conducted in the United
Kingdom were in accordance with UK Home Office Animals
(Scientific Procedures) Act (1986) and were in line with the
ARRIVE guidelines.21 Experiments were conducted in a blinded
fashion. Adult male rats (96 Sprague–Dawley rats, weight
180–200 g; Charles River, Margate, United Kingdom, group
housed 4 per cage) were housed in temperature-controlled
(20–22˚C) rooms in conventional cages under a 12-hour
light–dark cycle, lights on at 7 AM, and off at 7 PM. Rats were
allowed free access to standard rodent chow and water
throughout the day, apart from a fasting period 4 hours before
blood collections.
All animal studies performed at Medivir AB were in accordance
with relevant guidelines and regulations provided by the Swedish
Board of Agriculture. The ethical permissionswere provided by an
ethical board specialized in animal experimentation (Stockholm
South Animal Research Ethical Board). Adult male rats (6
Sprague–Dawley rats, 8 weeks of age; Charles River, Sulzfeld,
Germany) were housed (max 4 animals/cage) in conventional
cages under a 12-hour light–dark cycle. Rats were allowed
standard rodent diet and water ad libitum, except for a fasting
period overnight (from 17:00 in the evening to 11:00 in the
morning) before dosing with compound and for an additional 3
hours after dosing (in total 18 hours of fasting).
2.2. Intra-articular injections and behavioural testing
Intra-articular injection of MIA is associated with joint pathol-
ogy12,18 and pain behaviour4,22,37 comparable with clinical OA.
Investigators were blinded to themodel (except in the therapeutic
study where all rats received intra-articular injection of MIA) and
the treatments at all stages of the study. Rats were randomly
allocated to treatment groups, and then matching of control
measures was performed to ensure that groups were balanced.
All rats were habituated to testing area and equipment for 1 day
before any procedures were conducted.
Rats were briefly anesthetized (isoflurane 2.5%–3% in 100%
O2), and once areflexic received a single intra-articular injection of
1 mg MIA (Sigma, Gillingham, Dorset, United Kingdom) in 50-mL
saline or 50-mL saline through the infrapatellar ligament of the left
knee.37 Pain behaviour was assessed at baseline before injection
(day 0) and then after intra-articular injection twice weekly. Weight
distribution on the left (ipsilateral) and right (contralateral) hind limb
was assessed using an incapacitance tester (Linton Instrumen-
tation Diss, Norfolk, United Kingdom) as previously described.37
Changes in hind paw withdrawal thresholds (PWTs) were
assessed using von Frey monofilaments; Linton Instrumentation,
Norfolk, United Kingdom (Semmes-Weinstein monofilaments of
bending forces 0.4–26 g) as previously described.37
2.3. Formulation of L-006235
L-006235 was synthesized by GVK Bio (Hyderabad, India) and
formulated in 20%hydroxypropyl-beta-cyclodextrin (HP-b-CD) in
water at concentrations of 3 and 10 mg/mL.
2.4. Administration of L-006235 in the monosodium
iodoacetate model
In the first study, the effects of preventative treatment with 30-mg/
kg L-006235 were studied. In the second study, the effects of
preventative treatment with 30-mg/kg and 100-mg/kg L-006235
were studied. Rats received either vehicle (20% HP-b-CD) or L-
006235 starting 1 day before MIA injection. L-006235 was
administered orally twice a day for a total of 28 days (day21 to 27
after MIA injection). Pain behaviour was measured at baseline
before MIA injection and then twice a week until day 27. Pain
behaviour was measured before the first dose of the day and was
measured 24 hours after blood sampling (see below). In the third
study, L-006235 was given once pain behaviour was established
in the MIA model (therapeutic protocol). In this case, all rats
received oral treatment with vehicle (twice daily) for the first 14
days after intra-articular injection of MIA. On day 14, half of the
rats continued receiving vehicle and the other half received
L-006235 (100 mg/kg) twice daily for 27 days (day 14–41 after
MIA injection). As with the preventative study, pain behaviour was
measured before the MIA injection and then twice a week until
day 41 after injection. Similarly, behaviour was measured before
rats received the first oral dose each day and was measured 24
hours after blood sampling (see below). See Table 1 for group
sizes and Figure 1 for further study design.
Table 1
Group sizes for in vivo studies.
N
Study 1 (30 mg/kg L-006235 preventative)
Saline 1 vehicle 5
Saline 1 L-006235 6
MIA 1 vehicle 9
MIA 1 L-006235 10
Study 2 (30- and 100-mg/kg L-006235
preventative)
Saline 1 vehicle 6
MIA 1 vehicle 10
MIA 1 L-006235 (30 mg/kg) 9
MIA 1 L-006235 (100 mg/kg) 9
Study 3 (100-mg/kg L-006235 therapeutic)
MIA 1 vehicle 10
MIA 1 L-006235 (100 mg/kg) 10
MIA, monosodium iodoacetate.
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2.5. Blood collection
Blood was collected from the L-006235–treated animals for
bioanalysis of L-006235 on day 8, 22, and 27 after MIA
induction in the first study, on day 9 and 27 after MIA induction in
the second study and on day 40 after MIA induction in the third
(therapeutic) study (app. 500 mL). Blood was collected through
the tail vein at 1, 2, 3, 6, and 24 hours after the dose. In total, 1 to
3 blood samples were collected from each rat for bioanalysis of
L-006235. In the first study, samples were collected on day 8
and on day 22 at 2 hours after dose, and a third sample was
collected on day 27 at 24 hours after dose. In the second study,
one sample was collected at 1, 3, or 6 hours after dose at the
first sampling occasion (day 9), and a second sample was
collected 2 hours after dose on day 27. In the third study, one
sample was collected at 3, 6, or 24 hours after dose on day 40/
41. Blood was collected from all animals into separate Li-
heparin–coated tubes for plasma separation and placed in
room temperature for at least 30 minutes and protected from
light before centrifugation (10 minutes, 3600 rpm, at approxi-
mately 22˚C) within 1 hour of collection. The plasma samples
were immediately frozen and stored at minimum 220˚C until
analysis.
2.6. Bioanalysis of L-006235
Bioanalysis of L-006235 in rat plasmawas performedusing protein
precipitation followed by liquid chromatography-tandem mass
spectrometry detection. Plasma (10 mL) was mixed with 50 mL of
acetonitrile containing 100 nM of losartan and indinavir as internal
standards. The sample was centrifuged at 20,000g for 10 minutes
at 10˚C, and the supernatant was diluted 1:1 with MilliQ water.
Samples (5 mL) were injected onto the liquid chromatography-
tandem mass spectrometry system. The lower limit of quantifica-
tion (LLOQ) was 1 nM.
Pharmacokinetic (PK) data analysis was performed using the
software Phoenix WinNonlin (version 6.4; Certara). Pharmacoki-
netic data for L-006235 were analysed using noncompartmental
methodology, and the following PK parameters were reported:
(1) The area under the plasma concentration vs time curve from
time 0 to time 24 hours (AUC0–24) was calculated by the log/
linear trapezoidal method. The last sampling time point was
24 hours after dose.
(2) Maximal plasma concentration (Cmax).
(3) Time at maximal concentration (Tmax).
2.7. Histological staining and quantification of knee
joint pathology
On day 27 (preventative studies) or day 41 (therapeutic study),
rats underwent a final pain behaviour assessment and then were
euthanizedwith sodiumpentobarbital and transcardially perfused
with saline, followed by 4% paraformaldehyde (in 0.1-M
phosphate-buffered saline). Tibiofemoral joints with the synovia
attached were dissected and postfixed in paraformaldehyde for
48 hours and were then transferred into ethylenediaminetetra-
acetic acid (EDTA) solution for decalcification. Knees were then
sectioned for staining with haematoxylin and eosin.10 The
pathology scoring was performed on 3 stained sections per
rat10 as previously described.37 Cartilage damage and osteo-
phytes were scored using the Janusz method as previously
described.17 Cartilage damage was evaluated from 1 (minimal
superficial damage) to 5 (severe full-thickness degeneration to
tidemark). This scorewasmultiplied by the extent of cartilage area
involved (1/3, 2/3 or 3/3) to give a maximum score of 15.
Osteophytes were graded from 1 to 3 for mild (,40 mm),
moderate (40–160 mm), or severe (.160 mm). Synovitis was
scored to assess lining thickness and cellularity from a scale of
0 (lining layer, 1–2 cells thick) to 3 (lining layer.9 cells thick and/or
severe increase in cellularity).2
2.8. Synovial immunohistochemistry
Perfusion-fixated knee joint sections from the second preventative
experiment were labelled for the macrophage markers CD68 and
CD206 (2 sections per rat). Sections were first dewaxed in xylene
before being rehydrated in decreasing concentrations of ethanol
Figure 1. Study design timelines. (A) Timeline for the 2 independent preventative dosing studies. From day 21, rats received either vehicle or L-006235 (twice
daily). Rats received intra-articular (I.A.) injection of 1-mg MIA or saline into the left knee joint on day 0, and pain behaviour was quantified at baseline and twice
weekly. On day 26, rats received the final dose of treatment, and 24 hours later, final pain behaviour testing was conducted, and rats were humanly euthanized. (B)
Timeline for the therapeutic dosing study. Rats were dosed with either L-006235 or vehicle for 27 days starting from 14 days after MIA injection.
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(100%, 70%) before being incubated in distilled H2O. Sections
were then incubated in a Tris-EDTA buffer (10-mM Tris Base, 1-
mMEDTA, 0.05% Tween 20, pH 9.0) at 90˚C for 20minutes. After
returning to room temperature, sections were washed in 0.05M
Tris-buffered saline (TBS) before being blocked for 10 minutes
with a peroxidase blocking solution (BLOXALL, Vector Labs,
Burlingame, CA). Sections were washed again in 0.05M TBS
before being incubated for an hour in blocking serum (made up as
described in the Vectastain Elite ABC-HRP Kit [Vector Labs, PK-
6200]). Sections were then incubated in either 1:400 rabbit
antimannose (Abcam, Cambridge, United Kingdom: ab64693) or
1:400 mouse anti-CD68 (BioRad, Watford, United Kingdom:
MCA341GA) overnight. Sections were washed in 0.05M TBS
before being incubated with biotinylated secondary antibody for
45 minutes (made up as described in the Vectastain Elite ABC-
HRP Kit [Vector Labs, PK-6200]). After washes in 0.05M TBS,
sections were incubated in ABC reagent for 30 minutes (made up
as described in the Vectastain Elite ABC-HRP Kit [Vector Labs,
PK-6200]). Sections were then incubated in 3,39- diaminobenzi-
dine (DAB) peroxidase (Vector Labs: SK-4100) for 9 minutes.
Sections were then counterstained with Harris’s haematoxylin
before being dehydrated in increasing concentrations of ethanol
(70%, 100%). Sections were then mounted in DPX. Immunostain-
ing was visualised using a 340 objective (Zeiss, Oberkochen,
Germany: Axioskop-50) and imaged using a camera (Zeiss:
AxioCam MRc). Images used for analysis were taken from the
synovial lining and sublining layers on the medial side of the joint.
Images were converted to 8-bit and passed through a bandpass
filter. Imageswere thresholded, and the number of above threshold
particles was automatically counted. Counts were checked
manually to ensure consistency by the automated system. The
area of synovia images was calculated, and data are presented as
the number of positively stained cells per square millimeter.
2.9. Spinal cord glial cell immunofluorescence
Astrogliosis was assessed in the dorsal horn of the spinal cord
using perfused tissue from study 2: preventative 100-mg/kg L-
006235. The lumbar region of spinal cords from MIA rats treated
with either vehicle or L-006235 was sectioned (40-mm thick
sections). Immunolabelling for glial fibrillary acidic protein (GFAP)
was performed as previously described,35 with sections in-
cubated with 1:100 rabbit anti-GFAP (Abcam: ab48050) over-
night at room temperature. Sections were then developed after
being incubated with 1:300 Alexafluor 568 conjugated goat
antirabbit secondary antibody. Images were taken from the
superficial laminae of both the ipsilateral and contralateral dorsal
horn with a Zeiss 200M microscope using a 20 3 0.8 numerical
aperture objective lens. Images were autothresholded using the
Renyi entropy threshold value,19 and the suprathreshold areas of
labelling were then quantified using ImageJ software.
2.10. Quantitative real-time polymerase chain reaction
A separate cohort of rats were injected with either 1-mg/50 mL
MIA (n 5 6) or 50-mL saline (n 5 6). Twenty-eight days after
injection, rats were injected with sodium pentobarbital, and the
ipsilateral dorsal quadrant of the lumbar region of the spinal cord
was taken for analysis. Tissue was homogenised in TriReagent,
and RNA was collected (DirectZol miniprep kit; Zymo Research,
Irvine, CA) according to manufacturer’s instructions. After
extraction, 360 ng of total RNA was reverse transcribed using
AffinityScript reverse transcriptase (Agilent Technologies, Santa
Clara, CA) after manufacturer’s instructions. The reactions were
incubated at 25˚C for 10 minutes, 37˚C for 50 minutes, and 70˚C
for 15 minutes and then cooled on ice. Expression of the
cathepsin K gene was quantified as previously described.16
Primers and probes were designed using Primer Express v3
(Thermofisher, Waltham, MA) and synthesised by Eurofins
Genomics (Ebersberg, Germany). Cathepsin K forward primer
59- CAGCAGGATGTGGGTGTTCA -39, reverse primer 59- CA
CTGCGTGTCCAGCGTTT -39, Taqman probe 59- CTGCTA
CCCGTGGTGAGCTTTGCTCTATC -39, b-actin forward primer
59- AGCCATGTACGTAGCCATCCA -39, reverse primer 59-
TCTCCGGAGTCCATCACAATG -39, and Taqman probe 59-
TGTCCCTGTATGCCTCTGGTCGTACCAC -39.
2.11. Biomarker measurements
To assess the effects of L-006235 on biomarkers of bone
resorption and cartilage degradation, a single dose of L-006235
(100mg/kg) or vehicle (20%HP-b-CD) was administered through
oral gavage to a separate group of naive rats (n 5 3/group), and
blood (app. 100mL) was collected at baseline (before dosing) and
at 1, 3, 6, and 24 hours after dosing for biomarker analyses.
Levels of CTX-I and CTX-II in rat serum were measured using
commercially available kits (RatLaps [CTX-I] EIA and Serum Pre-
Clinical CartiLaps [CTX-II] ELISA; IDS Nordic, Herlev, Denmark),
according to the recommendations by the manufacturer.
2.12. Data analysis
Results are displayed as mean 6 SEM. All statistics were
calculated using Prism 5.0 or 7.0 software (Graphpad, La Jolla,
CA). Weight-bearing data were analysed with a 2-way analysis of
variance (ANOVA) with a Bonferroni post hoc test. Hind PWTs
were log-transformed before analysis with 2-way ANOVA with
a Bonferroni post hoc test. Differences between the area under
the curve for weight bearing and the log-transformed PWTs were
analysed using a 1-way ANOVA. Data were considered
significant if P values were less than 0.05. Differences in the
expression of the cathepsin K mRNA between saline and MIA-
injected rats, and the differences in GFAP immunoreactivity
between L-006235 and vehicle-dosed MIA rats were compared
with an unpaired t test. The statistical interaction between weight
bearing and each OA feature (cartilage damage, osteophytes, or
synovitis) was examined using a product term for Treatment
Group*OA Pathology. Statistical significance of the interaction
term provides a measure of the association between weight-
bearing pain behaviour and OA pathology, and the effect of
L-006235 on this association.
3. Results
3.1. Preventative L-006235 attenuates osteoarthritis
pain behaviour
Intra-articular injection of MIA resulted in a significant increase in
weight-bearing asymmetry and a lowering of hind PWTs over the
course of the model, compared with the saline-injected control
rats (supplementary Figure 1, available at http://links.lww.com/
PR9/A32). Two independent preventative dosing studies were
performed. Twice daily oral administration of L-006235 (30 mg/
kg), but not vehicle, significantly attenuated MIA-induced pain
behaviour (weight-bearing asymmetry and lowered PWTs) in the
first preventative study (Figs. 2A and B, supplementary Figure 1
for time course, available at http://links.lww.com/PR9/A32). In
the second preventative study, effects of twice daily oral
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administration of 30 and 100mg/kg L-006235 on the 2measures
of pain behaviour were compared. Time course data analysis
revealed that neither dose of L-006235 altered the early peak in
weight-bearing asymmetry at day 3, but both doses consistently
inhibited weight-bearing asymmetry from day 14 postmodel
induction onwards (Fig. 3A). The higher dose of L-006235 nearly
abolished weight-bearing asymmetry, compared with the effect
of vehicle treatment, at the later time points in the study (Fig. 3A).
L-006235 did not alter the initial drop in hind PWTs but did
prevent any further lowering in thresholds at the later time points
from day 7 onwards (Fig. 3B). There was a clear dose-related
effect of L-006235 for both measures of pain behaviour, which
was paralleled by a higher plasma exposure after oral adminis-
tration of the higher dose of L-006235 (100 mg/kg), compared
with the lower dose.
To ascertain whether the effects of L-006235 on pain
behaviour were related to effects on joint damage, histological
analysis was performed. Intra-articular injection of MIA was
associated with significant cartilage damage, synovitis, and
osteophyte score at the end of the study (Fig. 4). Neither dose
of L-006235 significantly altered the 3 parameters of joint damage
studied (Figs. 4A–C, supplementary Figures 2A and B, available
at http://links.lww.com/PR9/A32). However, after treatment of
MIA rats with the higher dose of L-006235, synovitis scores were
not significantly different compared with saline vehicle-treated
rats (Fig. 4B). The higher variability in the osteophyte score in MIA
vehicle-treated rats reduced the opportunity to detect any
potential effects of L-006235 on this parameter (Fig. 4C). To
understand the potential relationship between effects of
L-006235 on pain behaviour and joint pathology, a regression
analysis was performed. There was a significant interaction
coefficient of the effects of L-006235 on weight-bearing
asymmetry and synovitis score, but not for the cartilage damage
or numbers of osteophytes (Figs. 4D–F), suggesting that the
positive association between synovitis score and weight-bearing
asymmetry has been weakened by L-006235.
To further explore the effects of L-006235 on synovial
inflammation, immunohistochemistry analysis of the numbers of
macrophages in the synovium was performed. There was
a nonsignificant increase in the number of CD681 cells in the
synovium 27 days after MIA injection when compared with saline-
injected rats (supplementary Figure 2C, available at http://links.
lww.com/PR9/A32). In the group that received preventative
L-006235, the number of CD681 cells was lower compared with
vehicle-treated rats (supplementary Figure 2A, available at http://
links.lww.com/PR9/A32). The mannose receptor, CD206, has
Figure 2. Effect of preventative L-006235 (30 mg/kg) on MIA-induced weight-bearing asymmetry (A) and log-transformed ipsilateral hind paw withdrawal
thresholds (B) (study 1, Fig. 1 for study design). Group sizes were: saline1 vehicle, n5 5; saline1 L-006235, n5 6; MIA1 vehicle, n5 9; andMIA1 L-006235, n
5 10. Data are area under the curve andwere analysedwith a 1-way ANOVA: ****P, 0.0001 saline1 vehicle vsMIA1 vehicle; ###P, 0.0001, ##P, 0.01MIA1
vehicle vs MIA 1 L-006235. Data are presented as mean 6 SEM. ANOVA, analysis of variance.
Figure 3. Dose-related effects of L-006235 on MIA-induced weight-bearing asymmetry (A) and log-transformed ipsilateral hind paw withdrawal thresholds (B).
See Figure 1 for dosing details (study 2, Fig. 1 for study design). Group sizes were saline1 vehicle, n5 6; MIA1 vehicle, n5 10; MIA1 L-006235 (30mg/kg), n5
9; andMIA1 L-006235 (100mg/kg), n5 9. Data were analysed with a 2-way ANOVAwith a Bonferroni post hoc test: #P, 0.05; ###P, 0.001, ####P, 0.0001
MIA1 vehicle vs MIA1 L-006235 (30 mg/kg); *P, 0.05, **P, 0.01, and ****P, 0.0001 MIA1 vehicle vs MIA1 L-006235 (100 mg/kg). Data are presented as
mean 6 SEM. ANOVA, analysis of variance.
00 (2018) e685 www.painreportsonline.com 5
been used as a marker for macrophages that have a reparative
phenotype.42 There was a nonsignificant increase in the number
of CD2061 cells in the synovium of rats with MIA-induced joint
pain, compared with saline controls (supplementary Figure 2D,
available at http://links.lww.com/PR9/A32); however, there was
no significant effect of L-006235 on this cell count.
To investigate any potential effects of L-006235 on spinal pain
processing, expression of cathepsin K mRNA in the spinal cord
was quantified. Cathepsin K mRNA was expressed to a compa-
rable extent in the dorsal horn of the spinal cord in saline and
MIA-treated rats (supplementary Figure 3A, available at http://
links.lww.com/PR9/A32). Glial fibrillary acidic protein immuno-
fluorescence in the dorsal horn of the spinal cord is a marker of
mechanisms of central sensitization and is significantly in-
creased in the MIA model of OA pain.35 Preventative L-006235
(100 mg/kg) did not alter GFAP immunolabelling in the dorsal
horn of the spinal cord of rats 27 days after intra-articular
injection of MIA (supplementary Figure 3B, available at http://
links.lww.com/PR9/A32).
3.2. Therapeutic L-006235 attenuates osteoarthritis
pain behaviour
In the final study, we investigated whether L-006235 (100 mg/kg)
altered established pain behaviour in the MIAmodel. Time course
data analysis revealed that therapeutic dosing of L-006235 (100
mg/kg) had a significant inhibitory effect on weight-bearing
asymmetry, compared with MIA vehicle rats (Fig. 5A), but not on
hind PWTs (supplementary Figure 4, available at http://links.lww.
com/PR9/A32). Area under the curve analysis of weight-bearing
asymmetry confirmed comparable weight bearing asymmetry in
the 2 groups of MIA rats before L-006235 treatment (Fig. 5B) and
a significant inhibitory effect of L-006235 over the period of
treatment in MIA rats (Fig. 5C). At the final time point that pain
behaviour was assessed (day 41), cartilage and synovitis score
(Figs. 5D and E, supplementary Figure 5, available at http://links.
lww.com/PR9/A32) in MIA-treated rats were consistent with
levels at day 28 (Figs. 4A and B) and were significant compared
with the contralateral joint. However, the osteophyte score at day
41 was lower than that evident at day 28 and not significant
compared with the contralateral joint (Fig. 5F). Treatment with
L-006235 from day 14 to 41 after MIA injection did not alter any of
the joint features studied (Figs. 5D–F).
3.3. Bioanalysis of L-006235 plasma concentrations
Plasma concentrations of L-006235 were assessed in the 3
studies to confirm exposure to L-006235 between the studies.
The exposure to L-006235was similar in MIA- and saline-injected
rats for both preventative doses studied (Fig. 6A). Similar
exposures were observed between the 2 preventative studies
after administration of L-006235 at 30mg/kg twice daily (Fig. 6B).
The exposure observed after administration of L-006235 at 100
mg/kg twice daily in the therapeutic study tended to be lower than
the exposure observed in the preventative study (Fig. 6C). The
mean PK parameters were calculated from the second pre-
ventative study and are shown in Table 2. There was a more than
dose-proportional increase in exposure when increasing the
dose from 30 to 100 mg/kg (Table 2).
3.4. L-006235 attenuates serum CTX-I and II levels
Treatment of naı¨ve rats with L-006235 (100 mg/kg) significantly
reduced the serum CTX-I levels at 1 hour after dose by 20%,
Figure 4. (A–C) Effects of preventative L-006235 on MIA-induced cartilage damage (A), synovitis (B), and osteophyte score (C). See Figure 1 for study design.
Statistical analysis with a Kruskal–Wallis test and Dunn’s post hoc test: *P, 0.05, **P, 0.01, ****P, 0.0001 vs saline1 vehicle. Group sizes are as follows: saline
1 vehicle, n5 11; MIA1 vehicle, n5 18; MIA1 L-006235 (30 mg/kg), n5 19; and MIA1 L-006235 (100 mg/kg), n5 9. Data are presented as mean6 SEM.
(D–F)Weight-bearing plotted against cartilage damage (D), synovitis (E), and osteophyte score (F). The univariate lines of best fit for MIA1 vehicle (solid line) vsMIA
1 L-006235 (dashed line) (both doses). The statistical interaction between weight bearing and each OA pathology feature was examined using a product term for
Treatment Group*OA Pathology. Statistical significance of the interaction term implies that themeasured association between weight-bearing pain behaviour and
cartilage damage (D) and synovitis score (E) was changed by L-006235.
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compared with baseline (Fig. 7A). In vehicle-treated naı¨ve rats,
serum CTX-I levels were instead increased by 6% at 1 hour,
compared with baseline. The reduction in CTX-I levels by L-
006235 was statistically significant vs baseline (P, 0.05) and vs
vehicle (P , 0.05). No significant reductions in CTX-I were
observed at 3 hours after L-006235 administration. Serum CTX-I
levels are known to vary on food intake, and thus the results at 6
and 24 hours after dose (when the animals were allowed food
again) were not conclusive. Similarly, serum CTX-II levels were
reduced in L-006235–treated rats at 1 hour (by 42%) and 3 hours
after dose (by 24%), compared with baseline (Fig. 7B). The
reductions were statistically significant vs baseline (P, 0.05) at 1
hour and statistically significant vs vehicle at 1 hour (P , 0.001)
and 3 hours (P, 0.05). The CTX-II levels returned to baseline at 6
hours after dose. In vehicle-treated rats, serum CTX-II levels were
increased by 26% and 19%, compared with baseline, at 1 hour
and 3 hours, respectively. Overall, the results indicate a signifi-
cant, but transient in vivo target engagement of cathepsin K by
L-006235.
4. Discussion
This study reports for the first time the beneficial effects of
a cathepsin K inhibitor on the development of pain behaviour in
awell-established rodentmodel ofOApain. Oral treatmentwith the
cathepsin K inhibitor L-006235 significantly attenuated the de-
velopment of pain behaviour in theMIAmodel of OApain. Inhibitory
effects of L-006235 were most evident on weight-bearing
asymmetry, which was significantly attenuated from day 14 and
thenmaintained for the duration of the study. Only the higher dose
of preventative L-006235 significantly blocked the lowering of hind
PWTs at the final 2 time points of the study. Therapeutic treatment
with L-006235 from 14 days after induction of the MIA model
significantly prevented further changes in weight-bearing asym-
metry; however, L-006235 did not significantly reverse the already
established weight-bearing asymmetry. In addition, therapeutic
treatment with L-006235 did not alter lowered hind PWTs in MIA
rats, compared with vehicle. Pharmacokinetic analysis confirmed
that the exposure to L-006235was higher at the 100-mg/kg dose,
compared with the 30-mg/kg dose.
The finding that L-006235 attenuates weight-bearing asym-
metry in the MIA model is consistent with an earlier report that
1-month administration of another cathepsin K inhibitor
(AZ12606133) reduced mechanosensitivity of joint afferent fibres
to non-noxious and noxious movement in the Dunkin–Hartley
guinea pig model of spontaneous OA.29 In both our behavioural
study and the earlier electophysiological study, the effects of the
cathepsin K inhibitor were relatively slow in onset suggestive of
mechanisms other than direct antinociceptive effects on the
sensory nerve responses. In our study, we also assessed po-
tential effects of L-006235 on spinal mechanisms of central
sensitization, which are known to accompany the lowered hind
PWTs in theMIAmodel. Previously, we have reported an increase
in the expression of GFAP in the dorsal horn of the spinal cord,35
which is an established marker of central sensitization.9 In this
study, the higher dose of L-006235 (100 mg/kg) did not
significantly alter GFAP immunofluorescence in the dorsal horn
of the spinal cord, suggestive of a lack of effect on at least some
aspects of central sensitization that may point to a more
peripheral site of action.
Figure 5. Effects of L-006235 on established MIA-induced weight-bearing asymmetry (study 3). Fourteen days after intra-articular injection of MIA rats received
oral vehicle or L-006235 (100mg/kg) twice daily until day 40 (n5 10 per group). Data are presented as a time course (A) and area under the curve analysis of the 14
days before (B) and 26 days after treatment (C). Group sizes were MIA1 vehicle, n5 10 and MIA1 L-006235, n5 10. Time course data were analysed with a 2-
way ANOVAwith a Bonferroni post hoc test: #P, 0.05, ###P, 0.001MIA1 vehicle vsMIA1 L-006235. Area under the curve data were analysed with a t test *P
, 0.05. Data are presented as mean6 SEM. (D–F) L-006235 treatment did not alter MIA-induced cartilage damage (D) or synovitis score (E) at day 41 after MIA
injection. There was no change in osteophyte score (F) and effects of L-006235 could not be determined. Group sizes were MIA1 vehicle (contralateral), n5 6;
MIA1 vehicle (ipsilateral), n5 10; andMIA1 L-006235 (100 mg/kg) (ipsilateral), n5 8). Statistical comparison of groups used a Kruskal–Wallis test with post hoc
Dunn’s comparison: *P , 0.05, **P , 0.01 vs contralateral knee. Data are presented as mean 6 SEM. ANOVA, analysis of variance.
00 (2018) e685 www.painreportsonline.com 7
Previous studies have focused on the effects of cathepsin K
inhibition on joint structure rather than functional pain responses.
Although the association between joint damage and pain
responses is weak, there is a significant association between
synovitis and human OA pain.38 In this study, the doses and
treatment schedule used with L-006235 did not significantly alter
cartilage damage, synovitis score, or osteophyte score in the MIA
model. Regression analysis did reveal an effect of L-006235 on
the relationship between changes in weight-bearing and synovitis
score, which may point to an action of L-006235 on inflammatory
pain mechanisms at the end of the study. Treated animals
displayed less pain behaviour than would be predicted by their
synovitis score, suggesting that L-006235 might reduce the pain
caused by inflammation. A limitation of our study is that we did not
investigate the potential effects of the treatment on the immune
response, which may then influence the pain behaviour. To
further explore possible direct effects of L-006235 on the
inflammatory pain response at the end of the study, immunohis-
tochemical analysis of knee joint sections quantified the numbers
of CD681 and CD2061 macrophages in the synovium of MIA
vehicle vs MIA L-006235–treated rats. However, these studies
were inconclusive, and we found no evidence for a significant
increase in either population of cells in the synovium in the MIA
model and no further change by the treatment. It is feasible that
this analysis was underpowered, lack of existing data on these
populations of cells in this model limited our ability to perform
a power calculation. Bone marrow macrophages are known to
Figure 6. Plasma concentrations of L-006235 (mM) at 1, 3, 6, and 24 hours after dose (h.a.d). Data were collected 8 and 22 days after MIA induction in the first
study, 9 and 27 days after MIA induction in the second study, and 40/41 days after MIA induction in the third study. (A) Plasma concentrations of L-006235 after
dosing with 30 and 100 mg/kg in MIA- or saline-injected rats. The results for the 30- and 100-mg/kg doses are from the first and second preventative study,
respectively. (B) Plasma concentrations after dosing with 30 mg/kg L-006235 in the first (gray circles) and second (black circles) preventative study. (C) Plasma
concentrations after dosing with 100-mg/kg L-006235 in the second preventative study (gray squares) and in the therapeutic study (black squares). Data are
presented as mean 6 SEM.
Table 2
Mean PK parameters for L-006235.
Model Dose (mg/kg) Tmax (h) Cmax (mM) AUC0–24 (mM·h)
MIA 30 1.0 0.7 6.8
MIA 100 1.0 5.8 49
Saline 100 1.0 6.9 39
PK parameters were calculated from the second preventative study after repeat oral dosing to MIA- or saline-
injected rats at 30- and 100-mg/kg L-006235.
MIA, monosodium iodoacetate; PK, pharmacokinetic.
8 L.N. Nwosu et al.·00 (2018) e685 PAIN Reports®
express cathepsin K and have been implicated in tumour pro-
gression in bone.15 The contribution of macrophages in the bone
to OA pain is unknown; it is feasible that these cells, or other cell
types within the synovium, are a direct or indirect target of this
treatment and underpin the inhibitory effects on pain behaviour.
Studies using imaging methods such as SPECT/CT to study-
activated macrophage involvement may shed light on the
mechanisms of action of cathepsin K inhibitors in the future.45
Cathepsin K is expressed by osteoclasts and has an essential
role in bone resorption in human and mice,1 and overexpression
is associated with spontaneous synovitis and cartilage de-
generation.30,33 Our study of the effects of L-006235 was based
on the mounting evidence of a contribution of osteoclasts to OA
pain behaviour. In previous work, effects of cathepsin K inhibition
on bone resorption were not associated with changes in
osteoclastogenesis or survival of osteoclasts,24,28 and therefore,
the effects of L-006235 on the number of osteoclasts were not
quantified in this study. Comparison of the different classes of
drugs, whichmodulate osteoclast function on pain behaviour and
joint pathology in models of OA and inflammatory arthritis,
highlights mechanistic differences. Unlike the bisphosphonates,
cathepsin K inhibitors attenuate osteoclastic activity without
altering numbers of osteoclasts and do not alter bone forma-
tion.39 Bisphosphonates have beneficial effects on joint pathol-
ogy and pain behaviour in models of OA. In our previous study,
effects of preventative treatment with zoledronate on pain
behaviour in the MIA model were comparable in magnitude with
the effects of L-006235; however, therapeutic treatment was not
studied.37 Significant preventative, and reversal, effects of
zoledronate on pain behaviour in MIA rats were reported in
a separate study.40 The time course of the effects of zoledronate
on pain behaviour was similar to those of L-006235 in this study.
However, there were marked differences in terms of joint
endpoints; at early time points zoledronate inhibited osteoclast-
mediated cartilage resorption, and at later stages of the model
treatment improved subchondral bone and cartilage integrity but
not synovitis.40 The bisphosphonate alendronate inhibited bone
resorption and had chondroprotective effects in a surgical model
of OA, although pain was not analysed.13
Previously, we reported beneficial effects of a modified version
of osteoprotegerin (OPG), which acts to sequester receptor
activator of nuclear factor kappa-Β ligand and inhibits the number
of subchondral bone osteoclasts, in the MIA model of OA pain.37
Osteoprotegerin-Fc prevented pain behaviour in the MIA model,
effects accompanied by a robust inhibition in cartilage damage
and synovial inflammation, and bone features of OA (osteoclast
number and osteophyte score).36 The magnitude of inhibitory
effects of preventative L-006235 on pain behaviour in the MIA
model presented herein were comparable with the effects of
OPG-Fc.37 In addition, the ability of L-006235 to halt further
progression of pain behaviour in the MIA model once treatment
commenced was also consistent with the therapeutic effects of
OPG-Fc in this model. However, unlike OPG-Fc, L-006235 did
not alter osteophyte score in the MIA model. The findings
presented herein are consistent with the lack of effect of
L-006235 on bone erosion in a model of inflammatory arthritis,41
which contrast the beneficial effects of OPG-Fc on this feature in
the inflammatory arthritis model.34 Overall, the differences in the
effects of OPG-Fc vs L-006235 on joint features in these models
of 2 different types of arthritis suggest thatmechanisms additional
to cathepsin K also contribute to changes in joint structure.
To date, most previous studies in OA models have focused on
the potential beneficial effects of cathepsin K inhibitors on
cartilage pathology. In the anterior cruciate ligament transection
(ACLT) model of OA in the rabbit L-006235 (50 mg/kg/d for 7
weeks from 1 week after surgery) significantly lowered urine CTX-
II levels at 3 weeks after treatment, an effect maintained until the
end of the study.14 After 7 weeks of L-006235 treatment, the
Mankin score of joint pathology was significantly lower and bone
features were improved, compared with vehicle-treated rab-
bits.14 Consistent with this finding, murine cathepsin K deletion
had chondroprotective effects in the ACLT model of OA
compared with wild-type controls; however, there were no
beneficial effects on osteophyte formation.14 Positive effects of
28 day treatment with the cathepsin K inhibitor SB-553484 on
cartilage damage in a canine model of OA have also been
reported.6 Similarly, prophylactic and therapeutic effects of the
potent and selective cathepsin K inhibitor MIV-711 on joint
pathology in the rabbit ACLT and dog partial medial meniscec-
tomy models were also recently reported.26 In the rabbit ACLT
model, MIV-711was given once daily for 7weeks, starting 1week
after surgery (similar protocol as for in the L-006235 study above)
and in the dog partial medial meniscectomy model for 28 days,
starting 1 day before surgery (similar protocol as for the SB-
553484 study above).26 The effects of L-006235 on histopathol-
ogy in the collagen-induced arthritis model in mice were also
evaluated in both prophylactic and therapeutic settings after
dosing with L-006235 at 25 mg/kg/d. Both cartilage and bone
damage, and clinical score, were significantly attenuated by
preventative L-006235, whereas a therapeutic treatment once
clinical signs of disease were established did not have significant
effects.41 On the basis of these previous studies, our PK data and
Figure 7. Effect of L-006235 on serum CTX-I (A) and CTX-II (B) levels after a single dose of 100 mg/kg to naive rats. Data were analysed with a 2-way ANOVA
followed by Bonferroni multiple comparison test: *P , 0.05. ***P , 0.001 L-006235 vs vehicle. Data are presented as mean 6 SEM (n 5 3/group). ANOVA,
analysis of variance.
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the engagement of L-006235 with cathepsin K reported herein, it
seems that the duration of treatment, and dose used in our study
(ie, up to 100 mg/kg twice daily for 28 days) was sufficient to
attenuate pain behaviour but not structural changes to the joint in
this model.
Our demonstration that the cathepsin K inhibitor attenuates the
development, and halts established, weight-bearing asymmetry
in the MIA model of OA pain supports the further investigation of
the analgesic potential of this class of drugs aswell as their effects
on joint structure. Although our univariate analysis indicated that
L-006235 altered the association between pain behaviour and
synovitis, this is likely mediated by a cell type other than CD681 or
CD2061 macrophages. It is feasible that the positive effects of
L-006235 on pain behaviour arise due to off-target effects.
However, the inhibitory effect of L-006235 on human cathepsin S
is 8 to 10mM, and onmouse cathepsin S is 2.4mM,32making this
an unlikely target for the doses and exposures achieved in this
study. Nevertheless, the lack of potency data for rat cathepsin S
means that we cannot rule out a species-specific effect of
L-006235. From a mechanistic perspective, the more limited
effects of L-006235 on lowering of hind PWTs in this study is not
consistent with the robust inhibitory effects of cathepsin S
inhibition on measures of allodynia in models of neuropathic
pain.5 Overall, our novel finding that cathepsin K inhibition is
analgesic in a clinically relevant model of OA pain provides
evidence for a new therapeutic target for OA pain.
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